Archived Medical News Stories

RSSArchived Drug Trial News Stories - May 2010

Date Title Comments Rating
2010-05-31 FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency 0 None
2010-05-31 Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine 0 None
2010-05-31 Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients 0 None
2010-05-31 Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010 0 None
2010-05-29 Sunitinib not effective in patients with papillary RCC: Researchers 0 None
2010-05-29 CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia 0 None
2010-05-28 Advaxis doses first patient in FDA-approved phase II CIN trial 0 None
2010-05-28 Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress 0 None
2010-05-28 VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010 0 None
2010-05-28 Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's 0 None
2010-05-28 Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH 0 None
2010-05-28 CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial 0 None
2010-05-28 ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine 0 None
2010-05-27 NOXXON Pharma closes €33 million Series D round of financing 0 None
2010-05-27 Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy 0 None
2010-05-27 YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC 0 None
2010-05-27 Pfizer plans recruitment halt to EMPHASIS-HF trial 0 None
2010-05-27 FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging 0 None
2010-05-27 Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer 0 None
2010-05-27 Patients with transformed lymphoma show positive response to lenalidomide: Research 0 None
2010-05-27 New study holds promise for patients with LCA 0 None
2010-05-27 Logical Therapeutics closes $16.9 million Series C equity financing round 0 None
2010-05-26 CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer 0 None
2010-05-26 Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development 0 None
2010-05-26 Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability 0 5
2010-05-26 Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016 0 None
2010-05-26 Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH 0 None
2010-05-26 Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept 0 None
2010-05-26 Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen 0 5
2010-05-26 GTx reports top line results from toremifene Phase III clinical trial for prostate cancer 0 None
2010-05-25 Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress 0 None
2010-05-25 CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers 0 5
2010-05-25 Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients 0 None
2010-05-25 Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010 0 None
2010-05-25 REDUCE trial data published in the online version of European Urology 0 4
2010-05-25 DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis 0 None
2010-05-25 ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO 0 None
2010-05-25 NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo 0 None
2010-05-25 Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS 0 None
2010-05-25 Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting 0 None
2010-05-25 Neuralstem updates progress of ongoing Phase I human clinical trial for ALS 0 5
2010-05-25 Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC 0 None
2010-05-24 Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA 0 None
2010-05-24 Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed 0 None
2010-05-24 Phase 1 clinical trial of OXY111A initiated 0 None
2010-05-24 Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA 0 None
2010-05-24 Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol 0 None
2010-05-21 Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC 0 None
2010-05-21 New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010 0 None
2010-05-21 ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO 0 None
2010-05-21 Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010 0 None
2010-05-21 Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program 0 None
2010-05-21 ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO 0 None
2010-05-21 Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO 0 None
2010-05-21 PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting 0 None
2010-05-21 Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN 0 None
2010-05-21 Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010 0 None
2010-05-21 New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting 0 None
2010-05-21 Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome 0 4.5
2010-05-21 Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO 0 None
2010-05-21 Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO 0 None
2010-05-21 ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting 0 None
2010-05-21 Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting 0 None
2010-05-21 Phase III PRIMA study data of Rituxan to be featured at 46th ASCO 0 None
2010-05-21 Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation 0 None
2010-05-21 Genentech to present new data for targeted cancer medicines at 46th ASCO 0 None
2010-05-21 Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO 0 None
2010-05-21 Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010 0 None
2010-05-21 Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO 0 None
2010-05-21 ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting 0 None
2010-05-21 Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients 0 None
2010-05-21 Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010 0 None
2010-05-21 Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010 0 None
2010-05-21 Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO 0 None
2010-05-21 Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer 0 None
2010-05-20 Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma 0 None
2010-05-20 Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial 0 None
2010-05-20 Update on Phase I clinical trials of Oncopore for treatment of cancer 0 None
2010-05-20 Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever 0 None
2010-05-20 Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies 0 None
2010-05-19 Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD 0 None
2010-05-19 Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010 0 None
2010-05-19 Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients 0 None
2010-05-19 Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS 0 None
2010-05-19 Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen 0 None
2010-05-19 Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials 0 None
2010-05-19 Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin 2 2
2010-05-19 Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product 0 None
2010-05-19 New multi-center follow-up study of NX-1207 for treatment of BPH to be completed 0 None
2010-05-19 Generex Biotechnology's Phase I study data of AE37 for prostate cancer published 0 None
2010-05-19 Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA 0 None
2010-05-19 Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder 0 4
2010-05-19 Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting 0 None
2010-05-19 Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer 0 None
2010-05-18 Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting 0 None
2010-05-18 Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial 0 None
2010-05-18 KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection 0 None
2010-05-18 Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine 0 None
2010-05-18 Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes 0 None
2010-05-18 Phase II ALSTAR trial: Talampanel is safe for ALS patients 0 5
2010-05-18 UMPIRE trial of Red Heart Pill launched to combat cardiovascular problems 0 5
2010-05-18 FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis 0 4.2
2010-05-17 BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron 0 None
2010-05-17 Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting 0 None
2010-05-17 FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF 0 None
2010-05-17 Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR 0 None
2010-05-17 Hemispherx Biopharma to conduct study of Ampligen antiviral in China 0 None
2010-05-17 ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial 0 None
2010-05-17 Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review 0 None
2010-05-17 Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer 0 None
2010-05-17 Tranzyme Pharma to present data on prokinetic agent TZP-101 in GI recovery at ASCRS 2010 0 None
2010-05-17 Polypill to be tested in new heart disease trial 1 None
2010-05-17 Roche to commence clinical study of TB-403 in patients with colorectal and ovarian cancer 0 None
2010-05-17 Treatment with MP-376 reduces P. aeruginosa in CF patients: Research 0 None
2010-05-15 Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections 0 5
2010-05-15 Merck, Cardiome Pharma show superiority of BRINAVESS to amiodarone injection 0 None
2010-05-14 Data from RGN-259 study published in Archives of Ophthalmology 0 None
2010-05-14 Phase 2a study results of Aerosurf for prevention of RDS in premature infants published 0 None
2010-05-14 Inhibitex reports net loss of $4.8M for first-quarter 2010 0 None
2010-05-14 International study to test effectiveness of celecoxib in preventing growth of precancerous polyps 0 None
2010-05-14 DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary liver cancer 0 None
2010-05-14 Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting 0 None
2010-05-14 Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010 0 None
2010-05-14 Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010 0 None
2010-05-14 RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug 0 None
2010-05-14 Derma Sciences first-quarter net sales up 23% to $12,844,382 0 None
2010-05-14 Chimerix commences first-in-human study of CMX157 for HIV 0 None
2010-05-13 Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED 0 None
2010-05-13 ARYx Therapeutics decreases first-quarter net loss to $6.4 million 0 None
2010-05-13 Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia 1 5
2010-05-13 Genta first-quarter net loss increases to $166.6 million 0 None
2010-05-13 Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010 0 None
2010-05-13 Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087 0 None
2010-05-13 Amarin reports cash balance of $44 million for first-quarter 2010 0 None
2010-05-13 Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates 0 None
2010-05-13 CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer 0 None
2010-05-13 Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule 0 None
2010-05-12 Avexa halts HIV drug trials 0 None
2010-05-12 GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010 0 None
2010-05-12 NovaBay first-quarter net loss increases to $1.6 million 0 None
2010-05-12 Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010 0 None
2010-05-12 Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials 0 None
2010-05-12 FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer 0 None
2010-05-12 Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD 0 None
2010-05-12 Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients 0 None
2010-05-12 Evotec first-quarter operating loss decreases 93% to € 1.5 m 0 None
2010-05-12 COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate 0 None
2010-05-12 NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents 0 None
2010-05-12 Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs 0 None
2010-05-12 Oncos Therapeutics completes € 4 million investment from HealthCap 0 4
2010-05-12 Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients 0 None
2010-05-12 Gilead Sciences board authorizes $5 billion common stock repurchase program 0 None
2010-05-12 Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services 0 None
2010-05-12 Update on Nymox Pharmaceutical's Phase 3 program for NX-1207 0 None
2010-05-12 Tianyin third-quarter revenue up 60% 0 None
2010-05-12 Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease 0 None
2010-05-12 Exelixis first-quarter revenues increase to $42.2 million 0 None
2010-05-12 Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients 0 None
2010-05-12 Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported 0 None
2010-05-11 Pro-Pharmaceuticals completes $6 million private placement with 10X Fund 0 None
2010-05-11 EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer 0 None
2010-05-11 China Pharma first-quarter revenue up 16% to $15.1 million 0 None
2010-05-11 DUSA Pharmaceuticals first-quarter total product revenues up 22% 0 None
2010-05-11 MediciNova announces $15 million senior secured term loan with Oxford Finance 0 None
2010-05-11 Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens 0 None
2010-05-11 Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference 0 None
2010-05-11 Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010 0 None
2010-05-11 Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million 0 None
2010-05-11 CrystalGenomics completes European Phase I SAD study of CG400549 antibiotic candidate 0 None
2010-05-10 Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn 0 None
2010-05-10 Enzon reports income from continuing operations of $20.8M for first-quarter 2010 0 None
2010-05-10 QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain 0 None
2010-05-10 Harbor BioSciences reports encouraging results from Triolex Phase IIa trials 0 None
2010-05-10 Immunomedics third-quarter revenues increase to $10.7 million 0 None
2010-05-10 European patent strengthens Soligenix' topically active steroid intellectual property portfolio 0 None
2010-05-10 Achillion reports lower net loss of $5.6M for first-quarter 2010 0 None
2010-05-10 features investment report on ARIAD Pharmaceuticals 0 None
2010-05-10 Lexicon Pharmaceuticals first-quarter revenues down 61% 0 5
2010-05-10 Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei 0 None
2010-05-07 Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting 0 5
2010-05-07 Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010 0 None
2010-05-07 Osiris Therapeutics reports net income of $2.4M for first-quarter 2010 0 None
2010-05-07 Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure 0 None
2010-05-07 Halozyme Therapeutics first-quarter net loss decreases to $11.8 million 0 None
2010-05-07 releases NexMed investment report 0 None
2010-05-07 Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010 0 None
2010-05-07 Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting 0 None
2010-05-07 Genzyme to initiate $2 billion stock buyback 0 None
2010-05-07 Nabi Biopharmaceuticals reports first-quarter net income of $5.5 million from continuing operations 0 None
2010-05-07 Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule 0 None
2010-05-06 Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex 0 None
2010-05-06 Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients 0 None
2010-05-06 PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis 0 5
2010-05-06 Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million 0 None
2010-05-06 Vical reports net loss of $8.5 million for first-quarter 2010 0 None
2010-05-06 Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin 0 None
2010-05-06 Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease 0 None
2010-05-06 CU-Boulder develops inhalable vaccine for measles prevention 0 None
2010-05-06 Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010 0 None
2010-05-06 ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE 0 None
2010-05-06 Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010 0 None
2010-05-06 Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010 0 None
2010-05-06 Positive results from Phase IIa clinical study of LIPO-102 0 None
2010-05-06 Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416 0 None
2010-05-06 Update on CEL-SCI's Phase III clinical trial of Multikine 0 None
2010-05-06 Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX 0 None
2010-05-05 Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients 0 None
2010-05-05 Rockwell Medical first-quarter sales up 17.1% 0 None
2010-05-05 Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma 0 None
2010-05-05 Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin 0 None
2010-05-05 AMRI first-quarter total revenue down 9% to $49.3 million 0 None
2010-05-05 Cadence Pharmaceuticals resubmits OFIRMEV NDA 0 None
2010-05-05 Merck acquires development, commercialization rights of ridaforolimus 0 None
2010-05-05 ARIAD restructures collaboration with Merck for ridaforolimus mTOR inhibitor 0 None
2010-05-05 Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine 0 None
2010-05-05 Archivel Farma to start phase II clinical trials of RUTI vaccine for Latent Tuberculosis 0 None
2010-05-05 UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine 0 None
2010-05-05 Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study 0 None
2010-05-05 StemCells first-quarter total revenue up 307% 0 None
2010-05-05 Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010 0 None
2010-05-05 ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial 0 None
2010-05-05 Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies 0 None
2010-05-05 S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors 0 None
2010-05-05 Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010 0 None
2010-05-05 Additional pivotal Phase 3 trial data for MoxDuo IR released 0 None
2010-05-05 Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH 0 None
2010-05-05 Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010 0 5
2010-05-05 BELLUS Health to discontinue NC-503 diabetes development program 0 None
2010-05-04 MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010 0 None
2010-05-04 Celldex reports net loss of $6.6 million for first-quarter 2010 0 None
2010-05-04 Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010 0 None
2010-05-04 Celsion reports $4.6 million net loss from operations for first-quarter 2010 0 None
2010-05-04 Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI 0 None
2010-05-04 Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: 0 None
2010-05-04 releases investment report on Vical 0 None
2010-05-04 Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS 0 None
2010-05-04 ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine 0 None
2010-05-04 Hologic commences enrollment in European trial of Gestiva for prevention of recurrent preterm birth 0 None
2010-05-04 Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010 0 None
2010-05-04 Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010 0 None
2010-05-04 Researchers present positive results of Phase II clinical trial of eliglustat tartrate 0 None
2010-05-04 Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010 0 None
2010-05-03 NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12 0 None
2010-05-03 NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis 0 None
2010-05-03 Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells 0 None
2010-05-03 Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting 0 None
2010-05-03 Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease 0 None
2010-05-03 ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM 0 5
2010-05-03 Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor 0 None
2010-05-03 BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development 0 None
2010-05-03 Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010 0 None
2010-05-03 AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010 0 None
2010-05-03 Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery 0 None
2010-05-03 Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments 0 None
2010-05-03 TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH 0 None
2010-05-03 SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit 0 None
2010-05-03 Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH 0 None
2010-05-03 Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study 0 3
2010-05-03 Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure 0 None
2010-05-03 Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials 0 None
2010-05-03 Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference 0 None
2010-05-03 FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer 0 None


262 posts
26 raters